{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:35:23Z","timestamp":1769819723374,"version":"3.49.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011805","name":"Correvio GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011805","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jgar.2021.12.016","type":"journal-article","created":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T20:33:03Z","timestamp":1640377983000},"page":"102-107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Glycopeptide resistance in Enterococcus spp. and coagulase-negative staphylococci from hospitalised patients in Germany: occurrence, characteristics and dalbavancin susceptibility"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0613-925X","authenticated-orcid":false,"given":"Michael","family":"Kresken","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingo","family":"Klare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas A.","family":"Wichelhaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Wohlfarth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franziska","family":"Layer-Nicolaou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3580-2105","authenticated-orcid":false,"given":"Bernd","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Werner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2021.12.016_sbref0001","series-title":"Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals, 2011\u20132012","year":"2013"},{"key":"10.1016\/j.jgar.2021.12.016_bib0002","doi-asserted-by":"crossref","DOI":"10.1007\/s100960000299","article-title":"Glycopeptide resistance in coagulase-negative staphylococci","volume":"19","author":"Biavasco","year":"2000","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.jgar.2021.12.016_bib0003","doi-asserted-by":"crossref","first-page":"ii15","DOI":"10.1093\/jac\/dki005","article-title":"Origin, structure, and activity in vitro and in vivo of dalbavancin","volume":"55","author":"Malabarba","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.12.016_bib0004","doi-asserted-by":"crossref","first-page":"e00058","DOI":"10.1128\/CMR.00058-18","article-title":"The enterococcus: a model of adaptability to its environment","volume":"32","author":"Garc\u00eda-Solache","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jgar.2021.12.016_bib0005","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1592\/phco.30.1.80","article-title":"A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin","volume":"30","author":"Guskey","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jgar.2021.12.016_bib0006","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1093\/jac\/dky235","article-title":"Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015\u201316","volume":"73","author":"Pfaller","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.12.016_bib0007","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ijantimicag.2017.11.008","article-title":"Dalbavancin in the treatment of different Gram-positive infections: a real-life experience","volume":"51","author":"Bouza","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2021.12.016_bib0008","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s15010-019-01354-x","article-title":"Real-world experience with dalbavancin therapy in Gram-positive skin and soft tissue infection, bone and joint infection","volume":"47","author":"Tobudic","year":"2019","journal-title":"Infection"},{"key":"10.1016\/j.jgar.2021.12.016_bib0009","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3390\/antibiotics10080915","article-title":"Determination of a tentative epidemiological cut-off value (ECOFF) for dalbavancin and Enterococcus faecium","volume":"10","author":"Weber","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jgar.2021.12.016_bib0010","year":"2006"},{"key":"10.1016\/j.jgar.2021.12.016_sbref0011","series-title":"Breakpoint tables for interpretation of MICs and zone diameters","year":"2021"},{"key":"10.1016\/j.jgar.2021.12.016_bib0012","series-title":"Performance standards for antimicrobial susceptibility testing","year":"2020"},{"key":"10.1016\/j.jgar.2021.12.016_bib0013","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/2047-2994-1-21","article-title":"Vancomycin-resistant vanB-type Enterococcus faecium isolates expressing varying levels of vancomycin resistance and being highly prevalent among neonatal patients in a single ICU","volume":"1","author":"Werner","year":"2012","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.jgar.2021.12.016_bib0014","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.mimet.2019.03.025","article-title":"Development of a multiplex-PCR to simultaneously detect acquired linezolid resistance genes cfr, optrA and poxtA in enterococci of clinical origin","volume":"160","author":"Bender","year":"2019","journal-title":"J Microbiol Methods"},{"key":"10.1016\/j.jgar.2021.12.016_bib0015","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2021.12.016_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100732","article-title":"Thirty years of VRE in Germany\u2014\u2018expect the unexpected\u2019: the view from the National Reference Centre for Staphylococci and Enterococci","volume":"53","author":"Werner","year":"2020","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.jgar.2021.12.016_sbref0017","series-title":"Antimicrobial resistance in the EU\/EEA (EARS-Net). Annual epidemiological report for 2019","year":"2020"},{"key":"10.1016\/j.jgar.2021.12.016_bib0018","doi-asserted-by":"crossref","unstructured":"Coombs GW, Daley DA, Mowlaboccus S, Lee YT, Pang S; Australian Group on Antimicrobial Resistance. Australian Group on Antimicrobial Resistance (AGAR) Australian Enterococcal Sepsis Outcome Programme (AESOP) Annual Report 2018. Commun Dis Intell (2018) 2020;44. doi: 10.33321\/cdi.2020.44.19.","DOI":"10.33321\/cdi.2020.44.19"},{"key":"10.1016\/j.jgar.2021.12.016_sbref0019","series-title":"Antibiotic resistance threats in the United States, 2019","year":"2019"},{"key":"10.1016\/j.jgar.2021.12.016_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164136","article-title":"Heteroresistant vancomycin intermediate coagulase negative Staphylococcus in the NICU: a systematic review","volume":"11","author":"Chong","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2021.12.016_bib0021","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cpdd.695","article-title":"Dalbavancin population pharmacokinetic modeling and target attainment analysis","volume":"9","author":"Carrothers","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.jgar.2021.12.016_bib0022","doi-asserted-by":"crossref","first-page":"7833","DOI":"10.1128\/AAC.01717-15","article-title":"Impact of glycopeptide resistance in Staphylococcus aureus on the dalbavancin in vivo pharmacodynamic target","volume":"59","author":"Lepak","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.12.016_bib0023","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1086\/427283","article-title":"Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by Gram-positive pathogens","volume":"40","author":"Raad","year":"2005","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521002897?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521002897?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:58:50Z","timestamp":1761991130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716521002897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":23,"alternative-id":["S2213716521002897"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2021.12.016","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glycopeptide resistance in Enterococcus spp. and coagulase-negative staphylococci from hospitalised patients in Germany: occurrence, characteristics and dalbavancin susceptibility","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2021.12.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}